$182 Million is the total value of Prosight Management, LP's 43 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 65.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PRTA | Sell | PROTHENA CORP PLC | $23,029,000 | +6.1% | 323,300 | -23.4% | 12.67% | -6.6% |
| KZR | Sell | KEZAR LIFE SCIENCES INC | $5,443,000 | -2.1% | 629,957 | -38.5% | 3.00% | -13.8% |
| VRTX | Sell | VERTEX PHARMACEUTICALS INC | $2,721,000 | -50.2% | 15,000 | -44.6% | 1.50% | -56.2% |
| HAE | Sell | HAEMONETICS CORP MASS | $2,705,000 | -69.7% | 38,319 | -71.4% | 1.49% | -73.4% |
| EHC | Sell | ENCOMPASS HEALTH CORP | $2,375,000 | -65.4% | 31,647 | -64.0% | 1.31% | -69.6% |
| PRQR | Sell | PROQR THRAPEUTICS N V | $2,362,000 | -16.6% | 282,256 | -32.8% | 1.30% | -26.6% |
| ZBH | Sell | ZIMMER BIOMET HOLDINGS INC | $1,903,000 | -62.4% | 13,000 | -58.7% | 1.05% | -67.0% |
| UNH | Sell | UNITEDHEALTH GROUP INC | $1,289,000 | -35.6% | 3,300 | -34.0% | 0.71% | -43.4% |
| Sell | APTOSE BIOSCIENCES INC | $154,000 | -65.2% | 70,563 | -46.9% | 0.08% | -69.2% | |
| ADMA | Exit | ADMA BIOLOGICS INC | $0 | – | -115,100 | -100.0% | -0.12% | – |
| CANO | Exit | CANO HEALTH INC | $0 | – | -23,200 | -100.0% | -0.18% | – |
| RPHM | Exit | RENEO PHARMACEUTICALS INC | $0 | – | -54,934 | -100.0% | -0.32% | – |
| XFOR | Exit | X4 PHARMACEUTICALS INC | $0 | – | -87,813 | -100.0% | -0.36% | – |
| OPCH | Exit | OPTION CARE HEALTH INC | $0 | – | -27,875 | -100.0% | -0.38% | – |
| NUVB | Exit | NUVATION BIO INC | $0 | – | -91,694 | -100.0% | -0.53% | – |
| Exit | AURINIA PHARMACEUTICALS INCcall | $0 | – | -67,200 | -100.0% | -0.54% | – | |
| Exit | AKUMIN INC | $0 | – | -327,680 | -100.0% | -0.64% | – | |
| CLOV | Exit | CLOVER HEALTH INVESTMENTS CO | $0 | – | -79,100 | -100.0% | -0.66% | – |
| EVH | Exit | EVOLENT HEALTH INCcl a | $0 | – | -52,023 | -100.0% | -0.69% | – |
| Exit | ALBIREO PHARMA INCcall | $0 | – | -32,900 | -100.0% | -0.72% | – | |
| MDT | Exit | MEDTRONIC PLC | $0 | – | -11,000 | -100.0% | -0.85% | – |
| ATIP | Exit | ATI PHYSICAL THERAPY INC | $0 | – | -173,276 | -100.0% | -1.03% | – |
| AUPH | Exit | AURINIA PHARMACEUTICALS INC | $0 | – | -130,000 | -100.0% | -1.05% | – |
| LHCG | Exit | LHC GROUP INC | $0 | – | -9,888 | -100.0% | -1.24% | – |
| QSI | Exit | QUANTUM SI INC | $0 | – | -227,391 | -100.0% | -1.74% | – |
| RCM | Exit | R1 RCM INC | $0 | – | -171,817 | -100.0% | -2.39% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-12
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ALDEYRA THERAPEUTICS INC | 19 | Q2 2023 | 6.2% |
| ALBIREO PHARMA INC | 18 | Q4 2022 | 9.2% |
| MEIRAGTX HOLDINGS PLC | 18 | Q3 2023 | 6.3% |
| KEZAR LIFE SCIENCES INC | 17 | Q3 2023 | 8.2% |
| ARENA PHARMACEUTICALS INC | 16 | Q4 2021 | 8.2% |
| IOVANCE BIOTHERAPEUTICS INC | 16 | Q1 2022 | 7.7% |
| CENTENE CORP DEL | 16 | Q3 2023 | 5.3% |
| CUE BIOPHARMA INC | 14 | Q1 2023 | 5.6% |
| PROTHENA CORP PLC | 13 | Q3 2023 | 13.6% |
| ZIMMER BIOMET HOLDINGS INC | 13 | Q3 2021 | 9.8% |
View Prosight Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| EXICURE, INC. | February 14, 2022 | 2,426,508 | 2.2% |
| Aldeyra Therapeutics, Inc. | February 12, 2021 | 908,488 | 2.3% |
| Teligent, Inc. | February 14, 2020 | 1,484,527 | 2.8% |
| Cidara Therapeutics, Inc. | February 14, 2019 | 245,764 | 0.9% |
| Eiger BioPharmaceuticals, Inc.Sold out | February 14, 2019 | 0 | 0.0% |
| Millendo Therapeutics, Inc. | February 14, 2019 | 256,739 | 2.0% |
| OvaScience, Inc. | October 26, 2018 | 1,991,100 | 5.6% |
| CHIMERIX INC | February 13, 2018 | 1,478,519 | 3.1% |
| Harvard Apparatus Regenerative Technology, Inc. | February 12, 2016 | 184,360 | 1.4% |
View Prosight Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-05-03 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G | 2024-01-02 |
| 13F-HR | 2023-11-14 |
View Prosight Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.